Salarius Pharmaceuticals Inc (SLRX) — Cash Flow-to-Debt Ratio
Salarius Pharmaceuticals Inc (SLRX) has a Cash Flow-to-Debt Ratio of -0.89x as of September 2025, meaning its operating cash flow of $-1.65 Million could theoretically repay -1% of its total liabilities ($1.85 Million) in one year. See Salarius Pharmaceuticals Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Salarius Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Salarius Pharmaceuticals Inc across 10 annual periods. Also explore Salarius Pharmaceuticals Inc (SLRX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Salarius Pharmaceuticals Inc (2015–2024)
Year-by-year debt coverage analysis for Salarius Pharmaceuticals Inc. For market capitalisation and broader financial context, see Salarius Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | — |